Important aspects of T‐cell collection by apheresis for manufacturing chimeric antigen receptor T cells

Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing

“…In a retrospective study across three trials, pediatric patients (N = 71) with ALC <1.5 £ 10 3 /mL yielded less than the target number of CD3+ cells, and researchers concluded that these patients may require processing of larger blood volumes [13]. Overall, the observed correlation between pre-collection CD3+ lymphocytes and successful leukapheresis has led some centers to set ALC thresholds between 100/mL and 500/mL and a minimum of 150/ mL for CD3+ T cells [54].…”

Implications of CAR‐T cell therapy on apheresis services: a Scottish perspective

“…There are, however, reported manufacturing failure rates, often secondary to inadequate collection, of up to 14% in lymphomas. 9,10 Further to optimal timing, product quality is a critical source of variability in T-cell product manufacturing and this is heavily impacted by clinical characteristics. Therefore, careful multidisciplinary assessment is critical.…”

Current state of therapeutic apheresis and cellular therapy education for transfusion medicine fellows in the United States

“…4 This field is expanding rapidly and effective HPC and MNC collection play a critical role in patient management. 5 Collected products can be further processed and manipulated in highly regulated CT laboratories. The increasing complexity in the fields of apheresis and CT emphasizes the importance of physician training in these areas.…”

“…Apheresis can also be used to collect different cellular blood component(s), such as hematopoietic progenitor cells (HPCs) or mononuclear cells (MNCs), for both transplantation and/or further manufacturing into CT products 4 . This field is expanding rapidly and effective HPC and MNC collection play a critical role in patient management 5 . Collected products can be further processed and manipulated in highly regulated CT laboratories.…”